Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Revenio Group OyjREVXF 82 3-Year RORE % is -5.01 as of Mar. 2026. GuruFocus rates REVXF with a GF Score™ of 82/100 and a GF Value™ of $40.97 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 777 Medical Devices & Instruments companies, Revenio Group Oyj ranks worse than 55.73% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Revenio Group Oyj's 3-Year RORE % for the quarter that ended in Mar. 2026 was -5.01%.
The industry rank for Revenio Group Oyj's 3-Year RORE % or its related term are showing as below:
REVXF's 3-Year RORE % is ranked worse than 55.73% of 777
companies
in the Medical Devices & Instruments industry
Industry Median: -4.07
vs REVXF: -5.01
Revenio Group Oyj (OTCPK:REVXF) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Revenio Group Oyj 3-Year RORE % Related Terms
Revenio Group Oyj 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Revenio Group Oyj's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Revenio Group Oyj's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Revenio Group Oyj (REVXF) has a 3-Year RORE % of -5.01 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Revenio Group Oyj and its competitors. According to the industry distribution chart, Revenio Group Oyj ranks #433 out of 777 companies in the Medical Devices & Instruments industry, placing it in the top 55.7%.
Is Revenio Group Oyj's 3-Year RORE % too high?
Revenio Group Oyj's current 3-Year RORE % is -5.01. Based on the distribution chart, Revenio Group Oyj ranks #433 out of 777 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Revenio Group Oyj has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #433 out of 777 companies for 3-Year RORE %. This places Revenio Group Oyj in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Revenio Group Oyj and its competitors. Revenio Group Oyj's current 3-Year RORE % is -5.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Based on GuruFocus' analysis, Revenio Group Oyj (REVXF) is currently considered Significantly Undervalued. The stock's GF Value™ is $40.97, compared to a current price of $16.41 — trading 59.9% below its estimated fair value. The current 3-Year RORE % is -5.01. Revenio Group Oyj's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Revenio Group Oyj (REVXF), the current 3-Year RORE % is -5.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (REVXF) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of $16.41 is trading 59.9% below its estimated GF Value™ of $40.97.
GuruFocus considers Revenio Group Oyj to be Significantly Undervalued.
Key valuation signals for REVXF:
3-Year RORE %: -5.01
GF Value™: $40.97 vs. price of $16.41 (59.9% below fair value)
No single metric tells the full story. See the REVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
82GF Score
Get the complete analysis for REVXF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVXF has been successfully added to your 
